These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 10091030

  • 1. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
    Isenberg HD, Alperstein P, France K.
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):81-6. PubMed ID: 10091030
    [Abstract] [Full Text] [Related]

  • 2. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
    Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
    [Abstract] [Full Text] [Related]

  • 3. Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.
    Visalli MA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2002-5. PubMed ID: 9687397
    [Abstract] [Full Text] [Related]

  • 4. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
    Song A, McCulley TJ, Lam BL, Feuer WJ, Miller D, Alfonso EC.
    Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 6. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin RJ, Slaughter SE, Leggett JE.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [Abstract] [Full Text] [Related]

  • 7. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
    Zhang L, Li XZ, Poole K.
    J Antimicrob Chemother; 2001 Oct; 48(4):549-52. PubMed ID: 11581236
    [Abstract] [Full Text] [Related]

  • 8. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA, Qadri SM, Ueno Y, Walters EA, Domenico P.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [Abstract] [Full Text] [Related]

  • 9. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H.
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [Abstract] [Full Text] [Related]

  • 10. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.
    Fass RJ, Barnishan J, Solomon MC, Ayers LW.
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1412-8. PubMed ID: 8726011
    [Abstract] [Full Text] [Related]

  • 11. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD, Alperstein P, France K.
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [Abstract] [Full Text] [Related]

  • 12. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [Abstract] [Full Text] [Related]

  • 13. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kaynar-Tascioglu J, Kaya B, Goktas P.
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [Abstract] [Full Text] [Related]

  • 14. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
    Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.
    Pendland SL, Messick CR, Jung R.
    Diagn Microbiol Infect Dis; 2002 Jan; 42(1):75-8. PubMed ID: 11821176
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.